Showing 401 - 420 results of 15,701 for search 'treating data', query time: 0.18s Refine Results
  1. 401

    OCT predictors of retinal atrophy in neovascular age-related macular degeneration treated with aflibercept by Oscar M. Gagliardi, Ludovico Alisi, Giacomo Visioli, Federica Dini, Giuseppe M. Albanese, Stefano Scordari, Marco Marenco, Alessandro Lambiase, Rosalia Giustolisi

    Published 2025-04-01
    “…AIM: To identify optical coherence tomography (OCT) features present at the diagnosis of neovascular age-related macular degeneration (nAMD) that could predict retinal atrophy (RA) and visual performance in patients treated with intravitreal aflibercept. METHODS: OCT data collected at the time of nAMD diagnosis (T0), after the first (T1) and third (T2) intravitreal aflibercept injection, and 5y post-diagnosis (T3) were analyzed. …”
    Get full text
    Article
  2. 402

    Methylation-based biological age and cardiotoxicity risk in breast cancer patients treated with trastuzumab by Jamila Mammadova, Alicia Richards, Adriana Gonzalez-Torriente, Evan R. Adler, Rachel J. Cruz, Stefanie Palfi, Dae Hyun Lee, Christine Sam, Mohammed Al-Jumayli, Anders Berglund, Jong Y Park, Mohammed Alomar, Jacob K. Kresovich

    Published 2025-05-01
    “…Epigenetic clocks and circulating leukocyte subsets were derived from MethylationEPIC BeadChip data, and candidate SNPs were measured using the Global Screening Array. …”
    Get full text
    Article
  3. 403
  4. 404
  5. 405
  6. 406

    Durvalumab activity in previously treated patients who stopped durvalumab without disease progression by Jean-Charles Soria, Ashok Gupta, Siddharth Sheth, Chen Gao, Nancy Mueller, Natasha Angra, Caroline Germa, Pablo Martinez

    Published 2020-10-01
    “…Background Limited data exist on potential clinical benefit with anti-programmed cell death ligand-1 (PD-L1) retreatment in patients who stop initial therapy for reasons other than disease progression or toxicity and develop disease progression while off treatment.Patients and methods NCT01693562 was a phase I/II study evaluating durvalumab monotherapy in advanced solid tumors. …”
    Get full text
    Article
  7. 407

    Cytokine profile of COVID-19 convalescent plasma and its relationship to outcome of treated patients by Michael P. Potapnev, A. V. Maximovich, I. A. Dunayeu, L. M. Hushchina, F. N. Karpenko

    Published 2025-04-01
    “…Materials and methods. The study included data from 111 patients with COVID-19 who received CCP. …”
    Get full text
    Article
  8. 408

    CYP2D6 genotype and outcome in tamoxifen treated early breast cancer by Linda Thorén, Jonatan D. Lindh, Espen Molden, Marianne Kristiansen Kringen, Jonas Bergh, Erik Eliasson, Sara Margolin

    Published 2025-07-01
    “…Clinical information was collected from medical records. Data on endocrine treatment, use of CYP2D6 inhibitors was retrieved from the Swedish Prescribed Drug Register. …”
    Get full text
    Article
  9. 409

    High-resolution analysis of the treated coeliac disease microbiome reveals strain-level variation by Jelle Slager, Hanna L. Simpson, Ranko Gacesa, Lianmin Chen, Ineke L. Tan, Jody Gelderloos, Astrid Maatman, Cisca Wijmenga, Alexandra Zhernakova, Jingyuan Fu, Rinse K. Weersma, Gieneke Gonera, Iris H. Jonkers, Sebo Withoff

    Published 2025-12-01
    “…CeD onset results from a multifaceted interplay of genetic and environmental factors. While recent data show that alterations in gut microbiome composition could play an important role, many current studies are constrained by small sample sizes and limited resolution.Methods To address these limitations, we analyzed fecal gut microbiota from two Dutch cohorts, CeDNN (128 treated CeD patients (tCeD), 106 controls) and the Lifelines Dutch Microbiome Project (24 self-reported tCeD, 654 controls), using shotgun metagenomic sequencing. …”
    Get full text
    Article
  10. 410

    Evaluation of grip strength in hook of hamate fractures treated with osteosynthesis. Is this surgical treatment necessary? by Claudia Lamas-Gómez, Laura Velasco-González, Aranzazu González-Osuna, Marta Almenara-Fernández, Luis Trigo-Lahoz, Xavier Aguilera-Roig

    Published 2019-03-01
    “…Results: The mean follow-up was 36 months (range, 12–144 months). All 13 cases were treated with ORIF of the hook of the hamate. Mean VAS pain score was 5 preoperatively (4–9) and 1 (0–2) postoperatively. …”
    Get full text
    Article
  11. 411
  12. 412

    Splenic volume as a predictor of survival in cancer patients treated with immune checkpoint inhibitors by Yunhua Zhang, Yunhua Zhang, Yunhua Zhang, Xin Fu, Lilong Zhang, Lilong Zhang, Lilong Zhang, Qing Zhou, Qing Zhou, Qing Zhou, Weixing Wang, Weixing Wang, Weixing Wang

    Published 2025-05-01
    “…The meta-analysis results revealed that subjects with higher spleen volumes had a significantly reduced OS (HR: 1.74, 95% CI: 1.12–2.72, p = 0.014) and PFS (HR: 1.35, 95% CI: 1.15–1.58, p < 0.001) compared to counterparts with lower volumes. Furthermore, the data clearly highlighted that patients with increases in splenic volume faced significantly poorer clinical outcomes, as indicated by reduced OS (HR: 1.83, 95% CI: 1.36–2.46, p < 0.001) and PFS (HR: 1.70, 95% CI: 1.28–2.25, p < 0.001) relative to those with decreases in splenic size.ConclusionA higher baseline spleen volume and an increase in spleen volume during ICI therapy were predictors of a poor prognosis in cancer patients treated with ICI.…”
    Get full text
    Article
  13. 413

    Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel by Frederick L. Locke, Tanya Siddiqi, Caron A. Jacobson, Sarah Nikiforow, Sairah Ahmed, David B. Miklos, Yi Lin, Matthew A. Lunning, Brian T. Hill, Armin Ghobadi, Zhen-Huan Hu, Michael T. Hemmer, Michael J. Zoratti, Suresh Vunnum, Jonathan Tsang, Clare Spooner, Harry Smith, Christine Fu, Anik Patel, Harry Miao, Shilpa A. Shahani, Debbie L. Mirjah, Hairong Xu, Marcelo C. Pasquini

    Published 2025-06-01
    “…We conducted a systematic literature review (SLR) and meta-analysis to identify differences in V2Vt in patients with R/R LBCL treated with axi-cel, tisa-cel, or liso-cel. The impact of V2Vt (<28 days vs ≥28 to <40 days vs ≥40 days) on effectiveness and safety outcomes was evaluated in patients treated with axi-cel enrolled in a post-authorization safety study using the Center for International Blood and Marrow Transplant Research data. …”
    Get full text
    Article
  14. 414
  15. 415
  16. 416

    Characterizations of multi-kingdom gut microbiota in immune checkpoint inhibitor-treated hepatocellular carcinoma by Longhao Zhang, Shanshan Wang, Yajun Liang, Xiaobo Yang, Haitao Zhao, Xinting Sang, Dongya Zhang, Zhou Lan, Hanping Wang, Ziyu Xun, Chenchen Zhang, Chengpei Zhu, Jiashuo Chao, Zilun Pu, Cong Ning, Xianzhi Jiang

    Published 2024-06-01
    “…Herein, we investigated the multi-kingdom microbiota characterization of the gut microbiome, mycobiome, and metabolome using metagenomic, ITS2, and metabolomic data sets of 80 patients with ICI-treated HCC.Results Our findings demonstrated that bacteria and metabolites differed significantly between the durable clinical benefit (DCB) and non-durable clinical benefit (NDB) groups, whereas the differences were smaller for fungi. …”
    Get full text
    Article
  17. 417

    [Translated article] Musculoskeletal injuries treated following the flood in October 2024 in Valencia, Spain by J.F. Garrido Ferrer, J. Diranzo García, X. Bertó Martí, L. Marco Díaz, L. Hernández Ferrando

    Published 2025-09-01
    “…Introduction: The aim of this study was to describe and analyze the musculoskeletal injuries treated at a tertiary hospital, resulting from the sudden flooding and landslides that occurred on October 29, 2024, in the province of Valencia, Spain. …”
    Get full text
    Article
  18. 418
  19. 419
  20. 420